CDK1-IN-9
CDK1-IN-9 is an orally active and selective CDK1 inhibitor with an IC50 of 5.5 nM. CDK1-IN-9 exhibits broad antiproliferative activity, particularly against HCT116 colon cancer cells. CDK1-IN-9 induces G2/M phase arrest and downregulates CDK1, cyclin B1, and the replication initiation factor CDC45. CDK1-IN-9 induces severe DNA replication stress, subsequently activating the p53 signaling pathway to trigger apoptosis. CDK1-IN-9 can be used for research on colon cancer, liver cancer and gastric cancer.
For research use only. We do not sell to patients.
- Formula: C16H17N7O3S2
- Molecular Weight:419.48
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Aurora Kinase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK1/cyclinB1 5.5 nM (IC50) |
CDK2/cyclinE 25.9 nM (IC50) |
CDK4/cyclin D 402.8 nM (IC50) |
Aurora A 77.8 nM (IC50) |
In Vitro
CDK1-IN-9 (compound 11I) (0.1-5 μM; 24-72 h) exhibits IC50s of 0.023 μM, 0.292 μM, 0.360 μM and 0.566 μM in HCT116 cell line, HepG2 cell line, SGC7901 cell line and normal keratinocyte line HaCaT, respectively[1].
CDK1-IN-9 (0.1-0.5 μM; 3 days) strongly suppresses the clonogenic survival of HCT116 cell line, HepG2 cell line and SGC7901 cell line, respectively[1].
CDK1-IN-9 (0.5 μM; 24-48 h) significantly impairs the migratory ability of HCT116 cells[1].
CDK1-IN-9 (0.01-0.1 μM; 72 h) induces G2/M arrest in the HCT116 cell line[1].
CDK1-IN-9 (0.1-0.5 μM; 72 h) induces G2/M arrest in HepG2 and SGC7901 cell lines[1].
CDK1-IN-9 (0.1-1 μM; 72 h) inhibits the CDK1/cyclin B1 kinase activity through a non-canonical pathway[1].
CDK1-IN-9 (1 μM; 72 h) inhibits cell division cycle protein 45 (CDC45) activity, causes DNA damage, and triggers apoptosis via the p53-mediated mitochondrial pathway, which can be reproduced by CDC45 knockdown in the HCT116 cell line[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HCT116 cell line, HepG2 cell line, SGC7901 cell line
-
Concentration:0.1 μM; 0.25 μM; 0.5 μM; 1 μM; 2.5 μM; 5 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Decreased the viability of HCT116, HepG2, and SGC7901 cells in a dose- and time-dependent manner.
-
Cell Line:HCT116 cell line
-
Concentration:0.5 μM
-
Incubation Time:24 h; 48 h
-
Result:Significantly impaired the migratory ability.
-
Cell Line:HepG2 cell line, SGC7901 cell line
-
Concentration:0.1 μM; 0.5 μM
-
Incubation Time:72 h
-
Result:Induced G2/M arrest in a concentration-dependent manner.
-
Cell Line:HCT116 cell line
-
Concentration:0.01 μM; 0.1 μM
-
Incubation Time:72 h
-
Result:Induced G2/M arrest in a concentration-dependent manner.
-
Cell Line:HCT116 cell line, HepG2 cell line, SGC7901 cell line
-
Concentration:0.01 μM; 0.1 μM; 0.5 μM
-
Incubation Time:72 h
-
Result:Induced apoptosis in a concentration-dependent manner.
-
Cell Line:HCT116 cell line
-
Concentration:0.1 μM; 0.5 μM; 1 μM
-
Incubation Time:72 h
-
Result:Reduced the protein levels of CDK1 and cyclin B1 in a concentration-dependent fashion.
Significantly reduced CDC45 expression.
Increased γH2AX accumulation.
Elevated both total and phosphorylated levels of p53.
Decreased the ratio of the anti-apoptotic protein Bcl-xL to the pro-apoptotic protein BAX.
Increased Cytochrome c release.
-
Cell Line:HCT116 cell line
-
Concentration:0.5 μM; 1 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Downregulated the transcriptional levels of CDK1 and cyclin B1.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c nude mice (4-6 weeks old; 16-20 g) received a subcutaneous injection of 1 × 107 HCT116 cells to establish a xenograft tumor model[1].
-
Dosage:3.3 mg/kg; 10 mg/kg; 30 mg/kg
-
Administration:i.g.; every day; for 14 days
-
Result:Significantly lower tumor volume compared with the control group.
Reduced tumor weight by 56.4% in 30 mg/kg group.
Did not have significant changes in mouse body weight or in the weights of major organs (heart, liver, spleen, lung, and kidney).
Showed no obvious pathological injury or toxicity in these tissues through histological examination.
Did not have significantly effect on serum biochemistry parameters (including ALT and AST).
Chemical Information
-
Molecular Weight 419.48
-
Formula C16H17N7O3S2
-
SMILES
S=C(N1N=C(NC2=CC=C(S(=O)(N)=O)C=C2)N=C1N)NC3=CC=CC=C3OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)